

NYRx Drug Class Coverage Overview: Sodium Glucose Co-Transporter 2 Inhibitors

NYRx Preferred Drug

Drugs in the Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors drug class are included on the [NYRx Preferred Drug List \(PDL\)](#) and are subject to prior authorization (PA) requirements:

Preferred Drugs	Non-Preferred Drugs	Prior Authorization/Coverage Parameters
VI. Endocrine and Metabolic Agents		
Sodium Glucose Co-Transporter 2 (SGLT2) InhibitorsST		
Farxiga® Invokamet® ¹ Invokamet® XR ¹ Invokana® Jardiance® Synjardy® ¹ Synjardy® XR ¹ Trijardy® XR ¹ Xigduo® XR ¹	Inpefa™ Segluromet® Steglatro®	STEP THERAPY (ST) <ul style="list-style-type: none"> Requires trial with metformin with or without insulin prior to initiating SGLT2 therapy unless there is a contraindication, or the drug is being used for an FDA-approved Medicaid covered indication other than, or in addition to, Type 2 Diabetes.

Coverage Criteria Requirements

- Preferred drugs will not require PA if the required coverage parameters, as outlined in the [PDL](#), are found in the member’s Medicaid claim history at the time of pharmacy claim submission. Non-preferred drugs will require PA.
- Step Therapy requirements outlined in the PDL are in response to the NYRx Drug Utilization Review Board (DURB) recommendation based on FDA labeling and/or clinical practice guidelines and include:
 - Trial with metformin with or without insulin prior to initiating SGLT2 Inhibitors therapy unless there is a contraindication, or the drug is being used for an FDA-approved Medicaid-covered indication other than, or in addition to, Type 2 Diabetes.

What Pharmacy Providers Need to Do

Pharmacy providers should become familiar with the SGLT2 Inhibitors coverage criteria and the [PDL](#) and incorporate this information when discussing the need for PA with prescribers.

What Prescribers Need to Do

Prescribers should become familiar with the SGLT2 Inhibitors coverage criteria and the [PDL](#) and incorporate this information when prescribing for Medicaid members.

Resources

- [NYRx Education & Outreach Website](#)
- [NYRx Preferred Drug List](#)
- [NYRx Prior Authorization Submission Guide](#)
- [NYRx Step Therapy](#)

Contact Information

The NYRx Education & Outreach Call Center is available by phone at 1-833-967-7310 or by email at NYRxEO@primetherapeutics.com from 8:00 AM to 5:00 PM ET, Monday through Friday, excluding holidays.

The NYRx Education & Outreach team hosts virtual office hours every week for stakeholders to ask questions related to NYRx and care coordination. Visit the [NYRx Education & Outreach website](#) for more information.